PubMed:33754144 / 0-192
Annnotations
Inflammaging
{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":192},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":192},"obj":"Sentence"}],"text":"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial."}
yangbin123xm_800_3
{"project":"yangbin123xm_800_3","denotations":[{"id":"T1","span":{"begin":37,"end":55},"obj":"DP"},{"id":"T4","span":{"begin":0,"end":12},"obj":"CI"}],"text":"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial."}
chenxin_473849_800_3
{"project":"chenxin_473849_800_3","denotations":[{"id":"T5","span":{"begin":0,"end":12},"obj":"CI"},{"id":"T15","span":{"begin":37,"end":55},"obj":"DP"}],"text":"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial."}